scholarly journals CyberKnife therapy of 24 multiple brain metastases from lung cancer: A case report

2013 ◽  
Vol 6 (2) ◽  
pp. 534-536 ◽  
Author(s):  
GUIQING YANG ◽  
YISHAN WANG ◽  
YUANYUAN WANG ◽  
SIXIANG LIN ◽  
DONGNING SUN
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Brain Metastases ◽  
Multiple Brain Metastases

scholarly journals Non‑small cell lung cancer with multiple brain metastases remains relapse‑free for more than 13 years: A case report

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Tatsu Matsuzaki ◽  
Shinnosuke Ikemura ◽  
Taro Shinozaki ◽  
Eri Iwami ◽  
Takahiro Nakajima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Multiple Brain Metastases

scholarly journals Non-small Cell Lung Cancer with Multiple Brain Metastases Treated with Radiosurgery and Erlotinib: A Case Report

Cureus ◽  
2017 ◽  
Author(s):  
Bilgehan Sahin ◽  
Teuta Mustafayev ◽  
Gokhan Aydin ◽  
Gorkem Gungor ◽  
Bulend Yapici ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Multiple Brain Metastases

A phase II study of anlotinib plus whole brain radiation therapy (WBRT) for advanced non-small cell lung cancer with multiple brain metastases.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21063-e21063
Author(s):  
Xiangzhi Zhu ◽  
Hua Tao ◽  
Ming Jiang ◽  
Meiqi Shi ◽  
Cheng Kong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Brain Metastases ◽  
Advanced Nsclc ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Free Survival ◽  
Multiple Brain Metastases ◽  
Common Grade

e21063 Background: The prognosis of non-small-cell lung cancer (NSCLC) patients(pts) with multiple brain metastases is poor. WBRT is the main treatment for the pts, but QUARTZ study showed that the efficacy of WBRT is unsatisfactory. The synergistic effect of the antiangiogenic therapy with radiation therapy has been well established. Anlotinib, an antiangiogenic multi-target TKI, had significantly improved progression-free survival (PFS) of advanced NSCLC with Brain Metastases. This study aimed to evaluate the efficacy and safety of anlotinib combined with WBRT in pts with brain metastases ( > 3) from advanced NSCLC. Methods: Advanced NSCLC pts with brain metastases ( > 3) who were histologically confirmed to be driver gene wild type or positive and pts who had received two or more previous treatments were eligible. Pts with meningeal metastasis were excluded. All pts were treated with anlotinib (12 mg, QD, day 1 to 14 of a 21-day cycle) combined with WBRT (DT 30Gy/12f), followed by maintenance therapy with anlotinib until disease progression or treatment intolerance. The primary endpoint was intracranial progression-free survival (iPFS). Secondary endpoints were extracranial PFS (ePFS), OS and toxicity. Results: As of 25 Jan 2021, 28 pts were enrolled. The median age was 57.5 years with 46.4% male. 89.3% of pts with adenocarcinoma. 21.4% pts harbored EGFR mutation. A total of 25 pts were included in efficacy analysis. In intracranial evaluation, ORR was 64.0%, DCR was 88.0%, median iPFS was 11.1 months (95% CI 5.9 to 12.1). In extracranial evaluation, ORR was 12.0%, DCR was 84.0%, median ePFS was 6.0months (95% CI 3.2 to 8.8). Most common grade 1-2 adverse events (AEs) were hypertension (67.8%), fatigue (64.2%)，anorexia (46.4%) and hand and foot skin reaction (37.5%). The most common grade 3-4 AEs were hypertension (12.5%), hand and foot skin reaction (10.7%) and fatigue (7.2%). No intracranial hemorrhage occurred during treatment. Dose adjustment due to AE occurred in 21.4% patients. Conclusions: This prospective study shows that the combination of anlotinib and WBRT for patients with multiple brain metastases after standard treatment resistance exhibited an effective therapeutic approach and manageable AEs. For further investigation, large sample and additional clinical trials are warranted. Clinical trial information: ChiCTR1900022093.

Gamma knife radiosurgery for multiple brain metastases from lung cancer

2009 ◽  
Vol 16 (5) ◽  
pp. 626-629 ◽  
Author(s):  
Seong-Hyun Park ◽  
Sung-Kyoo Hwang ◽  
Dong-Hun Kang ◽  
Sun-Ho Lee ◽  
Jaechan Park ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Brain Metastases ◽  
Gamma Knife ◽  
Gamma Knife Radiosurgery ◽  
Multiple Brain Metastases

Durable response by olaparib for a Japanese patient with primary peritoneal cancer with multiple brain metastases: A case report

2018 ◽  
Vol 45 (3) ◽  
pp. 743-747 ◽  
Author(s):  
Ikuko Sakamoto ◽  
Yosuke Hirotsu ◽  
Hiroshi Nakagomi ◽  
Atsushi Ikegami ◽  
Katsuhiro Teramoto ◽  
...  
Keyword(s):  
Case Report ◽  
Brain Metastases ◽  
Japanese Patient ◽  
Durable Response ◽  
Primary Peritoneal Cancer ◽  
Peritoneal Cancer ◽  
Multiple Brain Metastases
Sign in / Sign up

Export Citation Format

Share Document